Accessibility: Skip TopNav
Figure 1.
Change in FVC from Baseline of Bexotegrast 320 mg Over 12 Weeks in INTEGRIS-IPF; Mixed Model Repeat Measures Analysis – Modified Intent to Treat Population
Format
PNG
Source
Pliant Therapeutics, Inc.
Downloads
Original
Large
Medium
Small